Myezom 3.5 mg Injection
  1. Home
  2. Pharma Products
  3. Dr Reddy 's Laboratories Ltd
  4. Myezom 3.5 mg Injection

Myezom 3.5 mg Injection

Myezom 3.5 mg Injection contains bortezomib 3.5 mg, a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. It is administered by a qualified healthcare professional according to the prescribed treatment schedule. Bortezomib interferes with proteasome activity, which can lead to the death of abnormal cancer cells.

BUY NOW

Category

Myezom 3.5 mg Injection is used as part of specific treatment regimens for multiple myeloma and mantle cell lymphoma. Bortezomib blocks proteasomes, cellular structures responsible for breaking down proteins, causing abnormal cancer cells to accumulate proteins and undergo cell death. The medicine may be used alone or in combination with other anticancer medicines depending on the patient’s treatment plan. Dose, administration schedule, and treatment duration are determined by the treating oncologist, with appropriate blood and clinical monitoring during therapy.

Technical Specification

Specification Details
Active Ingredient Bortezomib
Strength 3.5 mg
Dosage Form Powder for Injection
Route Intravenous / Subcutaneous
Pack Size 1 Vial
Manufacturer/Marketer Dr. Reddy’s Laboratories Ltd.

Product Also Known As

Myezom 3.5 mg Injection, Myezom 3.5 Injection, Myezom Bortezomib Injection, Bortezomib 3.5 mg Injection, Bortezomib Multiple Myeloma Injection, Bortezomib Proteasome Inhibitor Injection